Stereotactic body radiotherapy for organ-confined prostate cancer (Q33528163)

27 July 2017

Stereotactic body radiotherapy for organ-confined prostate cancer (English)

1 reference

27 July 2017

0 references

1 reference

Alan J Katz

1

1 reference

27 July 2017

Michael Santoro

2

1 reference

27 July 2017

Richard Ashley

3

1 reference

27 July 2017

Ferdinand Diblasio

4

1 reference

27 July 2017

Matthew Witten

5

1 reference

27 July 2017

1 February 2010

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

1

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

start time

1 February 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2490-10-1

0 references

cites work

Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Image-guided radiosurgical ablation of intra- and extra-cranial lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Testicular dose from prostate cyberknife: a cautionary note

21 January 2018

1 reference

12 December 2020

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

1 reference

12 December 2020

Time of decline in sexual function after external beam radiotherapy for prostate cancer

1 reference

12 December 2020

Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique

1 reference

12 December 2020

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity

1 reference

12 December 2020

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

1 reference

12 December 2020

Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer

1 reference

12 December 2020

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

12 December 2020

Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2490-10-1

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2490-10-1

9 September 2019

1 reference

27 July 2017

1 reference